WallStreetZenWallStreetZen

NASDAQ: GILD
Gilead Sciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for GILD

Based on 9 analysts offering 12 month price targets for Gilead Sciences Inc.
Min Forecast
$75.00+11.89%
Avg Forecast
$82.00+22.33%
Max Forecast
$105.00+56.65%

Should I buy or sell GILD stock?

Based on 9 analysts offering ratings for Gilead Sciences Inc.
Hold
Strong Buy
1 analysts 11.11%
Buy
1 analysts 11.11%
Hold
7 analysts 77.78%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their GILD stock forecasts and price targets.

GILD stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-04-19
lockedlocked$00.00+00.00%2024-04-17
lockedlocked$00.00+00.00%2024-03-04
lockedlocked$00.00+00.00%2024-02-22
lockedlocked$00.00+00.00%2024-02-22
RBC Capital
Top 5%
96
HoldMaintains$75.00+11.89%2024-02-14
Barclays
Top 21%
80
HoldMaintains$80.00+19.35%2024-02-12
Cantor Fitzgerald
Bottom 16%
16
HoldMaintains$78.00+16.37%2024-02-07
Deutsche Bank
Top 33%
68
HoldInitiates Coverage On$75.00+11.89%2023-11-09

1 of 1

Forecast return on equity

Is GILD forecast to generate an efficient return?
Company
N/A
Industry
15.58%
Market
35.5%

Forecast return on assets

Is GILD forecast to generate an efficient return on assets?
Company
N/A
Industry
5.85%

GILD revenue forecast

What is GILD's revenue in the next 3 years based on estimates from 10 analysts?
Avg 1 year Forecast
$27.5B+1.37%
Avg 2 year Forecast
$28.0B+3.42%
Avg 3 year Forecast
$28.9B+6.41%
GILD's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

GILD earnings growth forecast

How is GILD forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
15.64%
Industry
71.96%
Market
21.77%
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
GILD's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

GILD revenue growth forecast

How is GILD forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
2.04%
Industry
8.73%
Market
10.16%
GILD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
GILD's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

GILD vs General Drug Manufacturer Stocks

TickerPricePrice TargetUp/downsideConsensus
GILD$67.03$82.00+22.33%Hold
GSK$41.24$46.00+11.54%Buy
BMY$48.99$55.73+13.75%Hold
SNY$47.69$55.00+15.33%Hold
BIIB$193.18$287.15+48.64%Buy
View Top General Drug Manufacturer Stocks

Gilead Sciences Stock Forecast FAQ

Is Gilead Sciences Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 9 Wall Street analysts covering (NASDAQ: GILD) stock is to Hold GILD stock.

Out of 9 analysts, 1 (11.11%) are recommending GILD as a Strong Buy, 1 (11.11%) are recommending GILD as a Buy, 7 (77.78%) are recommending GILD as a Hold, 0 (0%) are recommending GILD as a Sell, and 0 (0%) are recommending GILD as a Strong Sell.

If you're new to stock investing, here's how to buy Gilead Sciences stock.

What is GILD's revenue growth forecast for 2024-2026?

(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 2.04% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 8.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Gilead Sciences's revenue in 2024 is $27,116,000,000.On average, 10 Wall Street analysts forecast GILD's revenue for 2024 to be $34,243,512,548,138, with the lowest GILD revenue forecast at $33,862,944,598,020, and the highest GILD revenue forecast at $34,737,179,392,544. On average, 10 Wall Street analysts forecast GILD's revenue for 2025 to be $34,935,179,072,687, with the lowest GILD revenue forecast at $33,937,504,208,787, and the highest GILD revenue forecast at $35,956,482,543,729.

In 2026, GILD is forecast to generate $35,944,470,784,881 in revenue, with the lowest revenue forecast at $34,139,207,576,864 and the highest revenue forecast at $37,329,636,368,440.

What is GILD's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: GILD) forecast ROA is N/A, which is lower than the forecast US Drug Manufacturers - General industry average of 5.85%.

What is GILD's Price Target?

According to 9 Wall Street analysts that have issued a 1 year GILD price target, the average GILD price target is $82.00, with the highest GILD stock price forecast at $105.00 and the lowest GILD stock price forecast at $75.00.

On average, Wall Street analysts predict that Gilead Sciences's share price could reach $82.00 by Apr 19, 2025. The average Gilead Sciences stock price prediction forecasts a potential upside of 22.33% from the current GILD share price of $67.03.

What is GILD's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: GILD) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.